Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
  • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Definitions

• This invention relates to a percutaneous pharmaceutical composition containing a polypeptide compound having pharmacological activity, mainly central nervous system stimulating activity or hormonal activity. More particularly, this invention relates to an external drug which comprises a pharmaceutical composition containing a low molecular weight polypeptide drug which is hardly absorbed through the gastrointestinal tract in combination with one or more higher aliphatic compounds, said external drug being adapted to be absorbed through the skin in an optional region of the body to display its pharmacological action.
• hydrophilic drugs having low oil/water partition coefficients are poorly absorbed from the gastrointestinal tract and low in bioavailability.
• Hydrophilic polypeptide drugs have heretofore been administered as injections but since administration by injection must rely on the hand of specialists and causes pain to patients, it has been desired to develop preparations which can be easily administered by methods other than injection and will ensure sufficient bioavailability.
• studies have so far been conducted to improve the bioavailability of such drugs by oral, rectal and nasal administration but none of such preparations has proved sufficiently satisfactory in bioavailability and ease of use.
• the present inventors conducted studies to develop a method of increasing the absorption of drugs by a route other than oral, rectal, and nasal, and investigated the method of promoting the absorption of low molecular weight polypeptide drugs from the skin.
• the horny layer of the skin acts as a barrier to permeation of drugs and what is important is to find a way to increase the membrane (horny layer) permeability so as to allow drugs to pass the barrier.
• An approach to this problem of enhancing the membrane permeability of the skin is the development of an absorption promoting agent which has the ability to soften the horny layer, dilate the pores, or control the surface-active property of the skin.
• the present inventors tentatively added to various polypeptide drugs a variety of compounds known to cause the horny layer to retain water, such as aliphatic lower alcohols such as sorbitol, glycerin, propylene glycol, etc. or compounds known to soften the horny layer such as salicylic acid, methyl salicylate, etc. but could not obtain any substantial improvement in the percutaneous absorption of the drugs. Therefore, the present inventors attempted a systematic classification of compounds which were apparently effective in promoting the absorption of said polypeptide drugs and conducted a series of experiments. As a result, it was discovered that a certain group of higher aliphatic compounds are excellent absorption- promoting agents for polypeptide drugs.
• promotors While, among higher aliphatic compounds, mono-fatty acids of 10 to 20 carbon atoms and monovalent aliphatic alcohols of 10 to 20 carbon atoms are well known as excellent promotors being capable of increasing the percutaneous absorption of flufenamic acid which is a lipophilic drug, it was not known that these promotors also enhance the percutaneous absorption of hydrophilic polypeptide drugs.
• This invention is therefore concerned with a percutaneous pharmaceutical composition which comprises at least one member selected from the group consisting of aliphatic monocarboxylic acids of 5 to 30 carbon atoms, aliphatic monohydric alcohols of 10 to 22 carbon atoms, aliphatic monoamides of 8 to 18 carbon atoms and aliphatic monoamines of 10 to 16 carbon atoms in combination with a physiologically active polypeptide.
• the aliphatic monocarboxylic acids of 5 to 30 carbon atoms which are employed in accordance with this invention . are normal-aliphatic fatty acids ranging from valeric acid which contains 5 carbon atoms through melissic acid which contains 30 carbon atoms, including saturated, unsaturated, straight and branched fatty acids.
• the saturated fatty acids include those having 5 to 30 carbon atoms such as valeric acid, isovaleric acid, caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, lauric acid, myristic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, cerotic acid, montanic acid, melissic acid, etc.
• Particularly preferred are those fatty acids from caprylic acid which contains 8 carbon atoms through behenic acid which contains 22 carbon atoms.
• Unsaturated fatty acids include olefinic acids such as octenoic acid which contains 8 carbon atoms through arachidonic acid which contains 20 carbon atoms. Particularly preferred are laurolenic acid which contains 12 carbon atoms to arachidonic acid which contains 20 carbon atoms.
• the monohydric aliphatic alcohols of 10 to 22 carbon atoms which are employed in accordance with this invention include saturated, unsaturated and branched t alcohols such as capryl alcohol which contains 10 carbon atoms through behenyl alcohol which contains 22 carbon atoms.
• capryl alcohol which contains 10 carbon atoms through behenyl alcohol which contains 22 carbon atoms.
• lauryl alcohol which has 12 carbon atoms through stearyl alcohol which contains 18 carbon atoms.
• the aliphatic monoamides of 8 to 18 carbon atoms which are employed in accordance with this invention includes octylamide which contains 8 carbon atoms through stearylamide which contains 18 carbon atoms.
• the aliphatic monoamine of 10 to 16 carbon atoms which employed in accordance with this invention includes decylamine which has 10 carbon atoms through hexadecylamine which contains 16 carbon atoms.
• decylamine of 10 carbon atoms through dodecylamine of 12 carbon atoms are preferred.
• the effective proportion of said higher aliphatic compound (absorption promoting agent) is not less than 0.1% by weight, and the range of 1% by weight to 10% by weight is particularly desirable.
• the polypeptides are exemplified by peptides which comprise 2 to 10 peptide linkages.
• the polypeptides have a small oil/water partition coefficient and more particularly an octanol/water partition coefficient of not more than 0.1.
• the oil/water partition coefficient can be determined by the method described in, Robert E. Notari "Biopharmaceutics and pharmacokinetics", Marcel Dekker Inc., 1975, New York, U.S.A.
• physiologically active polypeptide there may be mentioned, for example, L-pyroglutamyl-L-histidyl-L-prolinamide (thyrotropin releasing hormone; hereinafter referred to briefly as TRH) or its salts, especially its tartrate [U.S. Patent No.
• LH-RH luteinizing'hormone-releasing hormones
• II luteinizing'hormone-releasing hormones
• D-aminoacid residue R 3 As examples of the D-aminoacid residue R 3 ,there may be mentioned the residues of alpha-D-aminoacids containing up to 9 carbon atoms (e.g. D-Leu, Ile, Nle, Val, Nval, Abu, Phe, Phg, Ser, Thr, Met, Ala, Trp, a-Aibu, etc.), which may have suitable protective groups (e.g. t-butyl, t-butoxy, t-butoxycarbonyl, etc.).
• suitable protective groups e.g. t-butyl, t-butoxy, t-butoxycarbonyl, etc.
• salts of the peptide (II) with acids as well as metal complex compounds of the peptide (II) may also be employed just as peptide (II).
• polypeptide examples include vasopressin, vasopressin derivatives ⁇ desmopressin [Folia Endocrinologica Japonica, 54, 5, pp. 676-6 9 1, (1978)] ⁇ , enkephalin, enkephalin derivatives [U.S. Patent 4,277,394; European Patent Application Publication No. 31567]and substance P.
• the percutaneous pharmaceutical composition can be produced by compounding or mixing with an absorption promoting agent.
• the proportion of said polypeptide in the percutaneous pharmaceutical composition is generally 0.0005 to 50% by weight, and 10 ug to 50 mg per dose unit.
• the base for use in the external drug preparation according to this invention includes polyalcohols such as propylene glycol, sorbitol, glycerin, polyethylene glycol, etc., begetable oils and fats such as olive oil, safflower oil, cottonseed oil, etc., animal oils and fats such as squalene, squalane, lanolin, etc., paraffins such as liquid paraffin, vaseline, etc., fatty acid esters such as isopropyl myristate, isopropyl palmitate, diethyl sebacate, etc., and cellosolve, methyl-cellosolve, etc.
• polyalcohols such as propylene glycol, sorbitol, glycerin, polyethylene glycol, etc.
• begetable oils and fats such as olive oil, safflower oil, cottonseed oil, etc.
• animal oils and fats such as squalene, squalane, lanolin, etc.
• the percutaneous absorption external drug may contain a component for prolonging the duration of blood concentration of the active component or a component for controlling the rate of percutaneous absorption, such as solid paraffin, beeswax, carnauba wax, hydrogenated castor oil, lanolin, polyethylene glycol (PEG-1500 and up), sperm wax, glyceryl monostearate, cholesterol, carboxypolymethylene, carboxymethylcellulose, carboxy- ethylcellulose, silicone resin and the like, in suitable proportions.
• a component for prolonging the duration of blood concentration of the active component or a component for controlling the rate of percutaneous absorption such as solid paraffin, beeswax, carnauba wax, hydrogenated castor oil, lanolin, polyethylene glycol (PEG-1500 and up), sperm wax, glyceryl monostearate, cholesterol, carboxypolymethylene, carboxymethylcellulose, carboxy- ethylcellulose, silicone resin and the like, in suitable proportions.
• such a percutaneous pharmaceutical composition containing said components can be applied to the human body surface, either as it is or as formulated into any of the hydrophilic and oleagenous ointments and emulsions.
• such pharmaceutical canposi- tion can be impregnated into,or deposited on,a suitable support material and applied to the skin in such application forms as an adhesive tape, sheet, patch or the like.
• the support material mentioned just above is exemplified by high polymer film, woven fabric, non-woven fabric, paper and so forth.
• the adhesive agent may be selected from among such materials as polyalkylvinylether, polyalkylacrylate, polyisobutylene, natural rubber, synthetic rubber and other types.
• a low molecular weight polypeptide drug which can hardly be absorbed through the gastrointestinal tract can now be caused to be absorbed into the human body by mere application to the skin without use of an injection syringe or relying on the oral route of administration, the pain of injection and side-effects can be avoided and the desired pharmacological effect can be ensured over a sustained time period.
• Each blood specimen was centrifuged and 0.05 ml of the plasma was put in a polyethylene minivial containing 5 ml of a toluenic scintillator and stirred. After standing, the total radioactivity of the plasma sample was measured with a ⁇ -ray scintillation spectrometer and the TRH equivalent concentration of the plasma ( ⁇ g.eq./ml) was calculated.
• the percutaneous absorption of TRH tartrate was evaluated in AUC6 (the area under the blood concentration-time curve during 0 to 6 hours).
• AUC6 the area under the blood concentration-time curve during 0 to 6 hours.
• the mean of T R H tartrate in the preparation containing the absorption promoting agent for 5 rats was 1.3 pg.eq.hr/ml. This value was approximately 8 times as large as the (0.16 ⁇ g.eq.hr/ml) of the preparation of Comparative Example 1. It is therefore apparent that the percutaneous absorption of TRH tartrate was remarkably improved by the addition of oleic acid according to this invention.
• a percutaneous absorption test was carried out in male SD-JCL rats with an average body weight of 250 g. Under pentobarbital anesthesia, the abdomen of each rat was clipped of hairs with an electric clipper and the sample was coated on the denuded abdominal area (5 x 4 cm).
• the collected venous blood was centrifuged and 0.2 ml of the plasma was extracted with 1 ml of 0.01 N-NaOH and 5 ml of chloroform. From a 4 ml portion of the chloroform layer, the chloroform was distilled off and the residue was dissolved by addition of 0.2ml of 0.05 M sodium acetate-acetonitrile-tetrahydrofuran (70:30:0.2, v/v). A 50 ⁇ l portion of the solution was applied to a liquid chromatograph to determine the concentration of clonidine. The ⁇ -Bondapak Cl8 column was used for this liquid chromatography. The percutaneous absorption of clonidine was evaluated in terms of AUC6 (area under the blood concentration-time curve of clonidine during 0 to 6 hours) and its multiple over the of the preparation of Comparative Example 1 was calculated.
• AUC6 area under the blood concentration-time curve of clonidine during 0 to 6 hours
• DN-1417 and 14 C-labeled DN-1417 were dissolved in a mixture of 30 mg of lauric acid which is an absorption promoting agent according to this invention and 169.2 mg of propylene glycol to prepare a coating sample.
• the percutaneous absorption test and evaluation in rats were performed in the same manner as Example 1.
• the value for the preparation according to the invention was 2.6 ⁇ g.eq.hr/ml whereas the value for a control, namely a propylene glycol-based preparation of DN-1417 which was free of the absorption promoting agent was 0.3 ug.eq.hr/ml.
• the absorption was thus
• TRH tartrate in the above preparation as used according to the procedure of this example was 2.22 ⁇ g.eq.hr/ml. This value was 14 times as high as the value of the control preparation according to Comparative Example 1, and the percutaneous absorption of TRH tartrate was remarkably promoted by ethanol wiping.
• TRH tartrate in the above preparation as used according to the procedure of this example was 6.06 ug.eq.hr/ml. This value was 38 times as high as the value of the control preparation according to Comparative Example 1 and the percutaneous absorption was remarkably promoted.
• TRH and 10 pCi of 3 H-labeled TRH were dissolved in a mixture of 169.5 mg of propylene glycol and 30 mg of oleic acid, which is one of the absorption promoting agents according to this invention to prepare a coating sample.
• the percutaneous absorption test and evaluation in rats were carried out in the same manner as Example 1.
• the value of this example was 1.4 ⁇ g.eq.hr/ml. This value was 8.7 times as large as the value of Comparative Example 1 (0.16 ug.eq.hr/ml), showing that the percutaneous absorption of TRH was remarkably enhanced by the addition of oleic acid according to this invention.
• TAP-144 150 ⁇ g of TAP-144 was added to a mixture of 180 mg of propylene glycol and 20 mg of lauric acid, which is one of the absorption promoting agents according to this invention, to prepare a coating sample.
• the percutaneous absorption test and evaluation in rats were carried out in the same manner as Example 1, except that ; the determination of TA P -144 was by radioimmunoassay.
• the value of this example was 6.20 ng.hr/ml, which was 12 times as large as the value (0.50 ng.hr/ml) of a control preparation which did not contain an absorption promoting agent. It is thus clear that the percutaneous absorption of TAP-144 was remarkably promoted by the . addition of lauric acid according to this invention.
• TRH tartrate 10 mg was dissolved in a mixture of 20 mg of oleic acid and 1970 mg of propylene glycol under heating to prepare a percutaneous pharmaceutical composition.
• the container was sealed and trimmed, and this trimmed part was coated with polyalkyl acrylate as an adhesive agent, followed by joining the coated part with a release paper to prepare a patch.

Applications Claiming Priority (4)

Publications (1)

Family

ID=26397927

Family Applications (1)

Country Status (1)

Cited By (13)

Citations (4)

• 1984
  • 1984-05-22 EP EP84303461A patent/EP0127426A1/fr not_active Withdrawn

Patent Citations (4)

Similar Documents

Legal Events